A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence

BACKGROUND: Of the only 20% of patients with resectable pancreatic ductal adenocarcinoma (rPDA), cancer recurs in 80% of cases. Epigenetic dysregulation is an early hallmark of cancer cells acquiring metastatic potential, and epigenetic modulators may reactivate tumor suppressor genes, delay recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Heumann, Thatcher R., Baretti, Marina, Sugar, Elizabeth A., Durham, Jennifer N., Linden, Sheila, Lopez-Vidal, Tamara Y., Leatherman, James, Cope, Leslie, Sharma, Anup, Weekes, Colin D., O’Dwyer, Peter J., Reiss, Kim A., Monga, Dulabh K., Ahuja, Nita, Azad, Nilofer S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719150/
https://www.ncbi.nlm.nih.gov/pubmed/36463226
http://dx.doi.org/10.1186/s13148-022-01367-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719150/
https://www.ncbi.nlm.nih.gov/pubmed/36463226
http://dx.doi.org/10.1186/s13148-022-01367-8

Ejemplares similares